Corbus Pharmaceuticals Holdings, Inc.
Index- P/E- EPS (ttm)-0.32 Insider Own0.20% Shs Outstand125.24M Perf Week59.12%
Market Cap41.91M Forward P/E- EPS next Y-0.30 Insider Trans29.57% Shs Float124.69M Perf Month-7.36%
Income-39.00M PEG- EPS next Q-0.07 Inst Own36.60% Short Float3.08% Perf Quarter-1.79%
Sales0.20M P/S209.54 EPS this Y73.90% Inst Trans-6.54% Short Ratio2.39 Perf Half Y-62.93%
Book/sh0.49 P/B0.70 EPS next Y2.40% ROA-35.20% Target Price1.98 Perf Year-80.73%
Cash/sh0.70 P/C0.49 EPS next 5Y- ROE-54.80% 52W Range0.21 - 2.29 Perf YTD-44.62%
Dividend- P/FCF- EPS past 5Y5.30% ROI-63.20% 52W High-85.11% Beta2.13
Dividend %- Quick Ratio5.90 Sales past 5Y-14.30% Gross Margin- 52W Low63.94% ATR0.04
Employees41 Current Ratio5.90 Sales Q/Q-92.10% Oper. Margin- RSI (14)52.84 Volatility25.42% 14.50%
OptionableYes Debt/Eq0.32 EPS Q/Q45.40% Profit Margin- Rel Volume0.78 Prev Close0.35
ShortableYes LT Debt/Eq0.22 Earnings- Payout- Avg Volume1.61M Price0.34
Recom2.70 SMA2011.25% SMA50-11.49% SMA200-52.84% Volume1,250,568 Change-1.93%
Sep-08-20Downgrade ROTH Capital Buy → Neutral $40 → $3
Sep-08-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-08-20Downgrade Jefferies Buy → Hold $18 → $2.50
Sep-08-20Downgrade BTIG Research Buy → Neutral
Jul-07-20Initiated ROTH Capital Buy $40
Jun-17-20Initiated BTIG Research Buy $22
Mar-26-20Initiated Nomura Buy $12
Apr-05-19Initiated Jefferies Buy
Mar-20-19Initiated Oppenheimer Outperform $28
Jan-11-19Reiterated Cantor Fitzgerald Overweight $36 → $38
Dec-26-18Initiated H.C. Wainwright Buy $24
Dec-07-18Initiated RBC Capital Mkts Outperform $23
Oct-24-18Initiated B. Riley FBR Buy $22
Jan-19-18Initiated Raymond James Outperform $24
Dec-14-17Reiterated Cantor Fitzgerald Overweight $24 → $28
Nov-08-17Reiterated Noble Financial Buy $16 → $20
Sep-29-17Resumed Noble Financial Buy $16
Mar-30-17Reiterated Cantor Fitzgerald Overweight $17 → $24
Nov-15-16Reiterated JMP Securities Mkt Outperform $9 → $20
Nov-11-16Reiterated Noble Financial Buy $19
May-11-22 08:00AM  
May-10-22 09:25AM  
Apr-08-22 01:05PM  
Mar-31-22 09:51AM  
Mar-18-22 10:12AM  
Mar-17-22 10:41AM  
Mar-11-22 08:05AM  
Mar-08-22 06:15PM  
Mar-02-22 07:00AM  
Jan-14-22 09:38AM  
Jan-12-22 10:35AM  
Dec-31-21 09:58AM  
Dec-29-21 10:00AM  
Dec-07-21 10:00AM  
Nov-12-21 08:05AM  
Nov-11-21 08:05AM  
Nov-02-21 03:02PM  
Oct-21-21 09:30AM  
Sep-10-21 06:45AM  
Aug-12-21 09:45AM  
Jul-29-21 03:04PM  
Jun-24-21 08:05AM  
Jun-21-21 05:48PM  
Jun-18-21 08:38AM  
Jun-12-21 04:19AM  
Jun-03-21 02:42AM  
Jun-02-21 06:19AM  
Jun-01-21 12:26PM  
May-25-21 08:05AM  
May-19-21 09:20AM  
May-17-21 08:34AM  
May-11-21 08:05AM  
May-03-21 03:01PM  
Apr-20-21 08:05AM  
Mar-30-21 08:05AM  
Mar-18-21 12:00PM  
Mar-15-21 02:30PM  
Mar-10-21 12:59AM  
Mar-09-21 08:05AM  
Mar-08-21 08:05AM  
Mar-04-21 12:30PM  
Feb-11-21 11:29AM  
Feb-02-21 10:44AM  
Jan-20-21 08:05AM  
Jan-14-21 08:30AM  
Jan-12-21 08:49AM  
Jan-09-21 02:16AM  
Dec-07-20 10:43PM  
Dec-04-20 08:44AM  
Dec-01-20 10:28AM  
Nov-16-20 09:54AM  
Nov-12-20 08:05AM  
Nov-11-20 10:00AM  
Nov-10-20 03:31PM  
Nov-09-20 10:27AM  
Nov-03-20 08:05AM  
Oct-29-20 12:35PM  
Oct-23-20 08:05AM  
Oct-21-20 08:05AM  
Oct-08-20 08:05AM  
Oct-07-20 10:46AM  
Oct-06-20 07:05AM  
Oct-04-20 09:46AM  
Sep-25-20 08:53AM  
Sep-24-20 09:54AM  
Sep-10-20 10:01AM  
Sep-08-20 10:00AM  
Sep-04-20 09:40AM  
Aug-25-20 09:19AM  
Aug-24-20 06:30AM  
Aug-20-20 10:17AM  
Aug-16-20 08:15AM  
Aug-14-20 10:31AM  
Aug-06-20 07:05AM  
Aug-05-20 09:25AM  
Aug-03-20 08:05AM  
Jul-30-20 08:05AM  
Jul-29-20 08:05AM  
Jul-21-20 10:02AM  
Jul-17-20 04:21PM  
Jul-15-20 02:38PM  
Jul-08-20 08:05AM  
Jul-05-20 09:58PM  
Jun-29-20 08:05AM  
Jun-22-20 08:05AM  
Jun-18-20 10:56AM  
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moran Sean F.Chief Financial OfficerMay 16Buy0.3012,0003,600179,272May 16 11:03 AM
Cohen YuvalChief Executive OfficerMay 16Buy0.2510,5002,62594,430May 16 10:41 AM
Moran Sean F.Chief Financial OfficerMar 10Buy0.3715,0005,550167,272Mar 10 11:47 AM
Millian Craig StuartChief Operating OfficerMar 10Buy0.3710,0003,70022,000Mar 11 11:23 AM
Cohen YuvalChief Executive OfficerMar 09Buy0.378,6003,18283,930Mar 09 10:37 AM